The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
HIV, HCV and Related Comorbidities in Rural Communities Affected by Opioid Injection Drug Epidemics in the United States: Building Systems for Prevention, Treatment and Control (UG3/UH3)
This FOA will support biphasic (i.e., two stage, multi-method) research projects that inform community response and promote comprehensive, integrated approaches to prevent HIV and hepatitis C virus (HCV) infection, along with associated comorbidities such as hepatitis B virus (HBV) infection and sexually transmitted diseases (STDs), among people who inject drugs (PWID) in rural US communities. Opioid injection and its consequences (e.g., HIV, HCV, HBV, STDs and overdose) are the primary foci here. These projects should yield evidence of the effectiveness of community response models and best practices in responding to opioid injection epidemics that can be implemented by public health systems in similar rural communities in the US.
The companion announcement to this FOA is RFA-DA-17-023 which will support building capacity for a laboratory to perform next generation sequencing (advanced molecular detection) using Global Hepatitis Outbreak and Surveillance Technology (GHOST), to be developed in collaboration with CDC’s Division of Viral Hepatitis.
- Letter of Intent Due Date(s): 30 days prior to the application due date
- Application Due Date(s): January 10, 2017
- AIDS Application Due Date(s): January 10, 2017
RFA-DA-17-014 Expiration Date January 11, 2017
Application budgets for UG3 projects must not exceed $400,000 in direct costs for any year of the project.
Application budgets for UH3 projects are not limited but need to reflect the actual needs of the proposed project.
The maximum project period is 5 years: up to 2 years for the first phase (UG3) and up to 3 years for the second phase (UH3).